Development and validation of a prognostic nomogram model in primary cutaneous and subcutaneous soft tissue angiosarcoma

References

• Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma. Lancet Oncol. 2010;11(10):983–991.
   PubMed Web of Science ®Google Scholar
• Yu J, Steiner FA, Muench JP, et al. Juxtathyroidal neck soft tissue angiosarcoma presenting as an undifferentiated thyroid carcinoma. Thyroid. 2002;12(5):427–432.
   PubMed Web of Science ®Google Scholar
• Conic RRZ, Damiani G, Frigerio A, et al. Incidence and outcomes of cutaneous angiosarcoma: a SEER population-based study. J Am Acad Dermatol. 2020;83(3):809–816.
   PubMed Web of Science ®Google Scholar
• Sharma A, Jung MK, Polce SA, et al. Surveillance epidemiology and end results (SEER) reported survival outcomes have a high accuracy and positive predictive value when tested using randomized controlled trials (RCTs) as gold standard. Int J Radiat Oncol Biol Phys. 2019;105(1):E467–E468.
   Web of Science ®Google Scholar
• Park SY. Nomogram: an analogue tool to deliver digital knowledge. J Thorac Cardiovasc Surg. 2018;155(4):1793.
   PubMed Web of Science ®Google Scholar
• Wang S, Yang L, Ci B, et al. Development and validation of a nomogram prognostic model for SCLC Patients. J Thorac Oncol. 2018;13(9):1338–1348.
   PubMed Web of Science ®Google Scholar
• Rouhani P, Fletcher CD, Devesa SS, et al. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer. 2008;113(3):616–627.
   PubMed Web of Science ®Google Scholar
• Buehler D, Rice SR, Moody JS, et al. Angiosarcoma outcomes and prognostic factors: a 25-year single institution experience. Am J Clin Oncol. 2014;37(5):473–479.
   PubMed Web of Science ®Google Scholar
• Florou V, Rosenberg AE, Wieder E, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019;7(1):213.
   PubMed Web of Science ®Google Scholar
• Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008;44(16):2433–2436.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Otsuka A, Kabashima K. Cutaneous angiosarcoma: update on biology and latest treatment. Curr Opin Oncol. 2018;30(2):107–112.
   PubMed Web of Science ®Google Scholar
• Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18(12):2030–2036.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Paulino AF, McGinn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003;98(8):1716–1726.
   PubMed Web of Science ®Google Scholar
• Lahat G, Dhuka AR, Lahat S, et al. Outcome of locally recurrent and metastatic angiosarcoma. Ann Surg Oncol. 2009;16(9):2502–2509.
   PubMed Web of Science ®Google Scholar
• Shin JY, Roh SG, Lee NH, et al. Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: systematic review and meta-analysis. Head Neck. 2017;39(2):380–386.
   PubMed Web of Science ®Google Scholar
• Sinnamon AJ, Neuwirth MG, McMillan MT, et al. A prognostic model for resectable soft tissue and cutaneous angiosarcoma. J Surg Oncol. 2016;114(5):557–563.
   PubMed Web of Science ®Google Scholar
• Trofymenko O, Curiel-Lewandrowski C. Surgical treatment associated with improved survival in patients with cutaneous angiosarcoma. J Eur Acad Dermatol Venereol. 2018;32(1):e29–e31.
   PubMed Web of Science ®Google Scholar
• Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14(6):1953–1967.
   PubMed Web of Science ®Google Scholar
• Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11(3):241–247.
   PubMed Web of Science ®Google Scholar
• Florou V, Wilky BA. Current and future directions for angiosarcoma therapy. Curr Treat Options Oncol. 2018;19(3):14.
   PubMed Web of Science ®Google Scholar
• Lahat G, Dhuka AR, Hallevi H, et al. Angiosarcoma: clinical and molecular insights. Ann Surg. 2010;251(6):1098–1106.
   PubMed Web of Science ®Google Scholar
• Singla S, Papavasiliou P, Powers B, et al. Challenges in the treatment of angiosarcoma: a single institution experience. Am J Surg. 2014;208(2):254–259.
   PubMed Web of Science ®Google Scholar
• Katsurahara M, Horiki N, Takei Y. Duodenal metastasis from subcutaneous angiosarcoma of the head: rare cause of obscure gastrointestinal bleeding. Dig Endosc. 2014;26(2):291.
   PubMedGoogle Scholar
• Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996;77(11):2400–2406.
   PubMed Web of Science ®Google Scholar
• Oxenberg J, Khushalani NI, Salerno KE, et al. Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: determining tumor behavior prior to surgical resection. J Surg Oncol. 2015;111(7):829–833.
   PubMed Web of Science ®Google Scholar
• Bernstein JM, Irish JC, Brown DH, et al. Survival outcomes for cutaneous angiosarcoma of the scalp versus face. Head Neck. 2017;39(6):1205–1211.
   PubMed Web of Science ®Google Scholar
• Morrison WH, Byers RM, Garden AS, et al. Cutaneous angiosarcoma of the head and neck. A Therapeutic Dilemma. Cancer. 1995;76(2):319–327.
   PubMed Web of Science ®Google Scholar
• Ogawa K, Takahashi K, Asato Y, et al. Treatment and prognosis of angiosarcoma of the scalp and face: a retrospective analysis of 48 patients. Br J Radiol. 1019;85:e1127–e1133.
   Google Scholar
• Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Sarcoma meta-analysis collaboration (SMAC). Cochrane Database Syst Rev. 2000;2:Cd001419.
   Google Scholar
• Naka N, Ohsawa M, Tomita Y, et al. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol. 1996;61(3):170–176.
   PubMed Web of Science ®Google Scholar
• Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13(10):1045–1054.
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Nakamura Y, Kawachi Y, et al. Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience. J Dermatolog Treat. 2014;25(5):419–423.
   PubMed Web of Science ®Google Scholar
• Fujisawa Y, Yoshino K, Kadono T, et al. Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study. Br J Dermatol. 2014;171(6):1493–1500.
   PubMed Web of Science ®Google Scholar
• Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987;59(5):1046–1057.
   PubMed Web of Science ®Google Scholar
• Chow W, Amaya CN, Rains S, et al. Growth attenuation of cutaneous angiosarcoma with Propranolol-Mediated β-Blockade. JAMA Dermatol. 2015;151(11):1226–1229.
   PubMed Web of Science ®Google Scholar
• Donghi D, Dummer R, Cozzio A. Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. Br J Dermatol. 2010;162(3):697–699.
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Nagai H, Nakamachi Y, et al. Refractory metastasis of cutaneous angiosarcoma showing complete response to o pazopanib. Eur J Dermatol. 2015;25(1):71–73.
   PubMed Web of Science ®Google Scholar
• Lu HJ, Chen PC, Yen CC, et al. Refractory cutaneous angiosarcoma successfully treated with sunitinib. Br J Dermatol. 2013;169(1):204–206.
   PubMed Web of Science ®Google Scholar
• Ulrich L, Krause M, Brachmann A, et al. Successful treatment of angiosarcoma of the scalp by intralesional cytokine therapy and surface irradiation. J Eur Acad Dermatol Venereol. 2000;14(5):412–415.
   PubMed Web of Science ®Google Scholar
• Wada M, Horinaka M, Yasuda S, et al. PDK1 is a potential therapeutic target against angiosarcoma cells. J Dermatol Sci. 2015;78(1):44–50.
   PubMed Web of Science ®Google Scholar
• Young RJ, Woll PJ, Staton CA, et al. Vascular-targeted agents for the treatment of angiosarcoma. Cancer Chemother Pharmacol. 2014;73(2):259–270.
   PubMed Web of Science ®Google Scholar